Axicabtagene ciloleucel for large B-cell lymphoma: clinical report

CADTH
Record ID 32018002233
English
Original Title: Axicabtagene ciloleucel for adults with relapsed or refractory large B-cell lymphoma
Authors' objectives: CADTH will conduct an HTA to assess the optimal use of axicabtagene ciloleucel for adults with relapsed or refractory NHL. The purpose of this HTA is to provide evidence-based information in the areas of clinical effectiveness, health economics, patients’ and caregivers’ perspectives and experiences, and implementation and ethical issues to support decision-making in the jurisdictions concerning the structure and provision of axicabtagene ciloleucel therapy in Canada. Each component of the HTA (i.e., Clinical Review, Economic Review, Patients’ Perspectives and Experiences, Ethics Review, and Implementation Analysis) will be conducted individually and collaboratively. This protocol describes the Clinical Review. The objective of this Clinical Review component is to assess the beneficial and harmful effects of axicabtagene ciloleucel for eligible types of relapsed or NHL in adults and to identify available evidence-based guidance for the use of axicabtagene ciloleucel in this population.
Details
Project Status: Completed
URL for project: https://cadth.ca/axicabtagene-ciloleucel-adults-relapsed-or-refractory-large-b-cell-lymphoma
URL for protocol: https://cadth.ca/sites/default/files/pdf/ct0002-axi-cel-for-clinical-protocol.pdf
Year Published: 2019
URL for published report: https://cadth.ca/sites/default/files/pdf/car-t/ct0002-clinical-report-redacted.pdf
URL for additional information: https://cadth.ca/axicabtagene-ciloleucel-adults-relapsed-or-refractory-large-b-cell-lymphoma
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Canada
Pubmed ID: 31886962
MeSH Terms
  • Lymphoma, Non-Hodgkin
  • Immunotherapy, Adoptive
  • Biological Products
  • Receptors, Chimeric Antigen
  • Lymphoma
  • Lymphoma, B-Cell
  • Antineoplastic Agents, Immunological
Keywords
  • Axicabtagene ciloleucel
  • Non-Hodgkin lymphoma
  • CAR T-cell therapy
Contact
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca
Copyright: <p>Canadian Agency for Drugs and Technologies in Health (CADTH)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.